SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Abgenix, Inc. (ABGX)
An SI Board Since December 1998
Posts SubjectMarks Bans
590 38 0
Emcee:  Henry Niman Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2904:12PM Abgenix beats by $0.01, ex items (ABGX) 13.07 +0.46: Reports Q3 (Sep) losbob zagorin-10/21/2003
289Abgenix Announces Third Quarter 2003 Financial Results Tuesday October 21, 4:00 bob zagorin-10/21/2003
288great discussion on this thread. i think the post announcement sell-off was overbob zagorin-10/21/2003
287Oops. <eom>fred hayes-10/21/2003
286Fred, read and evaluate. I have nothing more to say. Miljenko Message 19409916Miljenko Zuanic-10/20/2003
285Miljenko: >Sure that 100M is enough for ABGX work, on AZ's targets< Cafred hayes-10/20/2003
284I agree. If all firing on all cylinders, abgx would be able to get a better dealmopgcw-10/18/2003
283George, Sure that 100M is enough for ABGX work, on AZ's targets. Usually, bMiljenko Zuanic-10/17/2003
282I agree that it is a transfer of risk from abgx to az, but I am not sure it is amopgcw-10/17/2003
281There are many targets (including oncology) that are non-EASY (IF at all) druggaMiljenko Zuanic-10/17/2003
280<i>...an interim strategy of partnering...</i> I don't think thnigel bates-10/17/2003
279Abgenix's Big Deals Matthew Herper, 10.16.03, 3:46 PM ET NEW YORK - Some Icebrg-10/17/2003
278>>Not exactly. They get milestone & royalties>> But almost. I cIcebrg-10/17/2003
277<i>Instead they seem to be on their way to become a mAb-based super CRO prnigel bates-10/17/2003
276<i>AstraZeneca can convert them at <b>$3.00</b> per share, whitom pope-10/17/2003
275ABGX/AZN deal - no appetite for drug development. A look at the deal from the pIcebrg-10/17/2003
274<i>AZ bit late in decision making</i> I was interested by the commenigel bates-10/17/2003
273interesting juxtaposition. Some say it is better to be a fast follower than a pmopgcw-10/17/2003
272Curiosity: AMGN, with ongoing ABX-EGF license (and antibody deal for multiple taMiljenko Zuanic-10/17/2003
271Abgenix Conference Call pt 2 Raymond Withy, CEO, President and Director - Abgmopgcw-10/17/2003
270Abgenix Conference Call Boston, Oct 16, 2003 (CCBN StreetEvents) -- Event Transmopgcw-10/17/2003
269GS take on AZ deal: ABGX (IL/N): AstraZeneca alliance strategic for pipeline anmopgcw-10/16/2003
268AstraZeneca and Abgenix Announce Strategic Alliance to Discover and Develop AntiIcebrg-10/16/2003
267<<Under the amended agreement, Immunex will have decision-making authorityMiljenko Zuanic-10/14/2003
266Abgenix and Amgen Clarify Responsibilities for ABX-EGF Tuesday October 14, 4:04 Icebrg-10/14/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News